Kidney Res Clin Pract.
2019 Jun;38(2):176-185. 10.23876/j.krcp.18.0139.
Adipose tissue-derived mesenchymal stromal cells for treating chronic kidney disease: A pilot study assessing safety and clinical feasibility
- Villanueva S
- González
- Lorca E
- Tapia A
- Valentina López G
- Strodthoff R
- Fajre F
- Carreño J
- Valjalo R
- Vergara C
- Lecanda M
- Bartolucci J
- Figueroa F
- Khoury M
- Affiliations
-
- 1Laboratory of Molecular and Integrative Physiology, Faculty of Medicine, Universidad de Los Andes, Santiago, Chile.
- 2Department of Nephrology, Hospital Salvador, Santiago, Chile.
- 3Laboratory of Nano-regenerative Medicine, Faculty of Medicine, Universidad de Los Andes, Santiago, Chile. ffigueroa@uandes.cl
- 4Cells for Cells, Faculty of Medicine, Universidad de Los Andes, Santiago, Chile.
- 5Program for Translational Research in Cell Therapy, Universidad de Los Andes, Santiago, Chile.
- 6Consorcio Regenero, the Chilean Consortium for Regenerative Medicine, Faculty of Medicine, Universidad de Los Andes, Santiago, Chile.
- KMID: 2451867
- DOI: http://doi.org/10.23876/j.krcp.18.0139
Abstract
- BACKGROUND
Chronic kidney disease (CKD) is a growing public health concern, and available treatments are insufficient in limiting disease progression. New strategies, including regenerative cell-based therapies, have emerged as therapeutic alternatives. Results from several groups, including our own, have reported evidence of a supportive role for mesenchymal stromal cells (MSCs) in functional recovery and prevention of tissue damage in murine models of CKD. Prompted by these data, an open pilot study was conducted to assess the safety and efficacy of a single injection of autologous adipose tissue-derived MSCs (AT-MSCs) for treatment of CKD.
METHODS
AT-MSCs were infused intravenously into six CKD patients at a dose of 1 million cells/kg. Patients were stabilized and followed for one year prior to MSC infusion and one year following infusion.
RESULTS
No patients presented with adverse effects. Statistically significant improvement in urinary protein excretion was observed in AT-MSCs transplanted patients, from a median of 0.75 g/day (range, 0.15-9.57) at baseline to 0.54 g/day (range, 0.01v2.66) at month 12 (P = 0.046). The glomerular filtration rate was not significantly decreased post-infusion of AT-MSCs.
CONCLUSION
Findings from this pilot study demonstrate that intravenous infusion of autologous expanded AT-MSCs into CKD patients was not associated with adverse effects and could benefit patients already undergoing standard medical treatment.
